LVRNA 009
Alternative Names: LVRNA-009; SARS-CoV-2 mRNA Vaccine - Liverna TherapeuticsLatest Information Update: 12 Sep 2023
At a glance
- Originator Liverna Therapeutics
- Developer AIM Vaccine
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 21 Jun 2023 AIM Vaccine completes a phase II trial in COVID-2019 infections (Prevention) in China (IM) (NCT05352867)
- 30 Jan 2023 Phase-III clinical trials in COVID-2019 infections (Prevention) in Kenya (IM)(NCT05682638)
- 12 Jan 2023 AIM Vaccine plans a phase-III trial for COVID-2019 infections (Prevention, In adults, In the elderly) in February 2023 (IM, injection) (NCT05682638)